Indiana University Health Neuroscience Center

Indianapolis, Indiana 46202

3 studies enrolling now · 14 studies all time

What they study most

Amyloid, Biochemical Recurrence of Malignant Neoplasm of Prostate, Cognitive Dysfunction, Depressive Disorder, Major, Frontotemporal Dementia, Healthy Participants, Huntington's Disease, Lewy Body Disease, MMN, Major Depressive Disorder, Multifocal Motor Neuropathy (MMN), Multiple Sclerosis

Studies at this site

• A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) — Recruiting now
• A Study of Brenipatide in Participants With Opioid Use Disorder — Recruiting now
• A Study of Brenipatide in Adult Participants With Major Depressive Disorder — Recruiting now
• Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS) — Completed
• A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy — Running, not enrolling
• Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer — Completed
• A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) — Stopped early
• A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease — Completed
• A Study of TAK-071 in People With Parkinson Disease — Completed
• Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations — Stopped early
• Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021 — Stopped early
• Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease — Completed
• Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants — Completed
• Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS — Completed